Amplia’s CEO and Managing Director, Dr John Lambert recently caught up with Andrew Scott from Proactive Investors to discuss the Company’s December quarter results, and upcoming Phase 2 clinical trials of lead candidate, AMP945.
In describing the significance of the planned trials for the Company, Dr Lambert said:
“Phase 2 clinical trials in small molecule drug development, if successful, are very significant value inflections. This is the time where we show whether our drugs work or not, so 2022 is going to be very important when we start to see the data from these clinical trials.”
Watch the interview